This module uses fundamental data of Bone Biologics to approximate its Piotroski F score. Bone Biologics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Bone Biologics Corp. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Bone Biologics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Bone Biologics Altman Z Score, Bone Biologics Correlation, Bone Biologics Valuation, as well as analyze Bone Biologics Alpha and Beta and Bone Biologics Hype Analysis.
Bone
Piotroski F Score
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Cash Ratio
Cash Conversion Cycle
Cash Flow Coverage Ratios
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Begin Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change In Working Capital
Stock Based Compensation
Depreciation
Issuance Of Capital Stock
Common Stock Shares Outstanding
Total Assets
Net Debt
Cash
Cash And Short Term Investments
Liabilities And Stockholders Equity
Total Current Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Retained Earnings
Other Stockholder Equity
Total Liab
Common Stock
Short Long Term Debt Total
Other Current Assets
Short Term Debt
Property Plant And Equipment Net
Accounts Payable
Non Current Assets Total
Net Receivables
Non Current Liabilities Total
Accumulated Other Comprehensive Income
Net Invested Capital
Net Working Capital
Capital Stock
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Gross Profit
Cost Of Revenue
Depreciation And Amortization
Selling General Administrative
Research Development
Total Other Income Expense Net
Income Tax Expense
Interest Expense
Tax Provision
Net Interest Income
Net Income From Continuing Ops
Probability Of Bankruptcy
At this time, Bone Biologics' Debt To Assets are fairly stable compared to the past year. Debt Ratio is likely to climb to 347.01 in 2025, despite the fact that Net Debt is likely to grow to (2.6 M). At this time, Bone Biologics' Debt To Assets are fairly stable compared to the past year. Price Book Value Ratio is likely to climb to 0.39 in 2025, whereas Operating Cash Flow Per Share is likely to drop (43.85) in 2025.
At this time, it appears that Bone Biologics' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Bone Biologics is to make sure Bone is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Bone Biologics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Bone Biologics' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Bone Biologics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Bone Biologics in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
10.44
At this time, Bone Biologics' Book Value Per Share is fairly stable compared to the past year.
Bone Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bone Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bone Biologics' managers, analysts, and investors.
Environmental
Governance
Social
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.